British Association of Dermatologists Clinical Standards Unit. Revised U.K. guidelines for the management of cutaneous melanoma

Summary  These guidelines for management of cutaneous melanoma present evidence‐based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation. To reflect the collaborative process for the U.K., they are subject to dual publication in the British Journal of Dermatology and the British Journal of Plastic Surgery.1

[1]  F. Sim,et al.  Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. , 1986, Mayo Clinic proceedings.

[2]  A. Sober,et al.  Does biopsy type influence survival in clinical stage I cutaneous melanoma? , 1985, Journal of the American Academy of Dermatology.

[3]  A. Marghoob,et al.  Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. , 1996, Archives of dermatology.

[4]  M. Mihm,et al.  Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Association of Directors of Anatomic and Surgical Pathology. , 1998, Virchows Archiv : an international journal of pathology.

[5]  C. Balch,et al.  Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. , 1988, The New England journal of medicine.

[6]  M. Tucker,et al.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Kondziolka,et al.  Stereotactic radiosurgery for cerebral metastatic melanoma. , 1993, Journal of neurosurgery.

[8]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[9]  L. Carey,et al.  Treatment of melanoma metastases in the brain. , 1996, Seminars in surgical oncology.

[10]  N. Cascinelli,et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial , 1998, The Lancet.

[11]  Dr Alistair J. Cochran.  Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma: Association of Directors of Anatomic and Surgical Pathology , 1998, Pathology international.

[12]  R. Dobson,et al.  British Association of Dermatologists , 2014 .

[13]  M. Mihm,et al.  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. , 1993, Annals of surgery.

[14]  J. Melia,et al.  Cancer Research Campaign health education programme to promote the early detection of cutaneous malignant melanoma. I. Work‐load and referral patterns , 1995, The British journal of dermatology.

[15]  E. Paul,et al.  Congenital nevi less than or equal to 10 cm as precursors to melanoma. 52 cases, a review, and a new conception. , 1985, Archives of dermatology.

[16]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[17]  R. Grimley,et al.  Ilioinguinal block dissection for malignant melanoma , 1995, The British journal of surgery.

[18]  M. Weinstock,et al.  Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. , 1989, JAMA.

[19]  J. Thomas,et al.  Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma , 1996, The British journal of surgery.

[20]  Lack of effect of pregnancy on outcome of melanoma , 1991, The Lancet.

[21]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Sanders,et al.  Evaluation of staging workup in malignant melanoma. , 1989, Archives of surgery.

[23]  B K Armstrong,et al.  Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? , 1988, The Journal of dermatologic surgery and oncology.

[24]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Parkin Dm,et al.  Cancer Incidence in Five Continents. Comparability and quality of data. , 1992 .

[26]  A. Pathology,et al.  Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma , 1997, Virchows Archiv.

[27]  E. Paul,et al.  Congenital Nevi <10 cm as Precursors to Melanoma: 52 Cases, a Review, and a New Conception , 1985 .

[28]  Fei Liu,et al.  Lentigo maligna of the head and neck. Results of treatment by radiotherapy. , 1994, Archives of dermatology.

[29]  A. Marghoob,et al.  Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma. , 1995, Journal of the American Academy of Dermatology.

[30]  E. R. Farmer,et al.  NIH Consensus conference. Diagnosis and treatment of early melanoma. , 1992, JAMA.

[31]  J. Melia,et al.  Why some cases of retinopathy worsen when diabetic control improves , 1997, BMJ.

[32]  M. Atkins,et al.  Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Newton-Bishop,et al.  Survey of U.K. current practice in the treatment of lentigo maligna , 2001, The British journal of dermatology.

[34]  H. Zarour,et al.  Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. , 1995, Dermatology.

[35]  U. Ringborg,et al.  Prognostic factors in thin cutaneous malignant melanoma , 1994, Cancer.

[36]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Weitzel.  [Radiotherapy of melanoma]. , 1970, Schweizerische medizinische Wochenschrift.

[38]  U. Chetty,et al.  A rational approach to melanoma follow‐up in patients with primary cutaneous melanoma , 1999, The British journal of dermatology.

[39]  H. C. Williams,et al.  How do malignant melanomas present and does this correlate with the seven‐point check‐list? , 1991, Clinical and experimental dermatology.

[40]  J. A. Bishop,et al.  Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. , 1996, British Journal of Cancer.

[41]  A. Kopf,et al.  Treatment of lentigo maligna and lentigo maligna melanoma. , 1979, The Journal of dermatologic surgery and oncology.

[42]  D M Parkin,et al.  Cancer Incidence in Five Continents. Comparability and quality of data. , 1992, IARC scientific publications.

[43]  D. Bishop,et al.  How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? , 1993, Journal of the American Academy of Dermatology.

[44]  J. Melia,et al.  Early detection of cutaneous malignant melanoma in Britain. , 1995, International journal of epidemiology.

[45]  The British Association of Dermatologists guidelines for the management of skin disease , 1999, The British journal of dermatology.

[46]  G. Plewig,et al.  Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. , 2000, Journal of the American Academy of Dermatology.

[47]  W. Coleman,et al.  Treatment of lentigo maligna and lentigo maligna melanoma. , 1980, The Journal of dermatologic surgery and oncology.

[48]  R. Marks,et al.  Sunburn and melanoma: how strong is the evidence? , 1994, BMJ.

[49]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  V. Lees,et al.  Effect of initial biopsy procedure on prognosis in Stage 1 invasive cutaneous malignant melanoma: Review of 1086 patients , 1991, The British journal of surgery.

[51]  A. Hamblin,et al.  Antigen‐presenting capacity in normal human dermis is mainly, subserved by CDla+ cells , 1994, The British journal of dermatology.

[52]  M. J. Timmons.  Malignant melanoma excision margins: plastic surgery audit in Britain and Ireland, 1991, and a review. , 1993, British journal of plastic surgery.

[53]  A. Gage,et al.  Cryosurgery for lentigo maligna. , 1994, Journal of the American Academy of Dermatology.

[54]  N. Cox,et al.  British Association of Dermatologists , 2001 .

[55]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Wolf,et al.  Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck , 1996, Head & neck.

[57]  Sm,et al.  Risk Factors for , 2002 .

[58]  C. Grin,et al.  Pregnancy and the prognosis of malignant melanoma. , 1996, Seminars in oncology.

[59]  C. Balch,et al.  Thin Stage I Primary Cutaneous Malignant Melanoma , 1988 .